75.3 F
New York
Sunday, September 19, 2021

Teva [NYSE: TEVA] Gets EU Authorization for Seffalair and BroPair Spiromax

Must read

ReneSola [NYSE: SOL] and Eiffel’s Joint Venture Buys Its First 200 MW Project Portfolio

ReneSola Ltd disclosed that European Solar Energy Development JV has finalized the purchase of its first batch of solar projects with a combined...

Square [NYSE: SQ] Launch its Early Access Program in Spain

Square, Inc. which has earned a reputation as a software, payments, and hardware solution firm for all types of businesses disclosed that it...

Ideanomics [NASDAQ: IDEX] Decides to Increase Stake in Energica

Ideanomics, Inc. disclosed that it has decided to ink an agreement with Energica Company. As per the agreement, the firm has decided to...

L3Harris’ [NYSE: LHX] Robot Chosen to Protect US Air Force Bases Around the Globe

L3Harris Technologies, Inc. disclosed that it has received a huge contract from US Air Force. The firm revealed that its robot will now...

Teva Pharmaceutical Industries Limited [NYSE: TEVA] disclosed that it has got EU Marketing Authorization for Seffalair Spiromax and its duplicate BroPair Spiromax. This is the greatest accomplishment for the firm. It will deliver new cure options to healthcare experts who aid people living with conditions such as asthma.

Furthermore, the firm has committted to empower the victims who has been living with asthma to mange their condition. At the same time, it also provide cost-effective cure to healthcare systems.

Launch of Seffalair and BroPair Spiromax

Teva Pharmaceutical disclosed that it has scheduled the rollout in Spain, Portugal, UK, and Switzerland. Since the rollout of DuoResp Spiromax, the Spiromax inhaler has been well supported by healthcare experts and sufferers. Additionally, Inhaler technique and therapy devotion are important factors in enhancing results for asthma sufferers.

About Seffalair and BroPair Spiromax

Seffalair Spiromax and BroPair Spiromax are designated as a routine therapy for asthma in grown-ups and youngsters at the age of 12 years and older not appropriately controlled with inhaled corticosteroids and ‘as required’ inhaled short-acting β2 agonists.

More articles

Latest article

Tower Semiconductor [NASDAQ: TSEM] Introduces Breakthrough LiDAR Technology

Tower Semiconductor Ltd. has introduced a breakthrough development of LiDAR IC technology created for sophisticated driver-assistance systems (ADAS) and ultimately self-driving cars. The...

KKR [NYSE: KKR] Decides to Divest Riata Corporate Park

KKR & Co. Inc. has disclosed that it has decided to divest the Riata Corporate Park. Riata Corporate Park is an eight-building, 688,100...

3D Systems [NYSE: DDD] Unveil VisiJet Wax Jewel Red

3D Systems Corporation has launched the VisiJet Wax Jewel Red. It will allow jewelry makers to design and create more sophisticated, lasting patterns....

Xerox [NYSE: XRX] Announces Transfer of Stock Exchange Listing to Nasdaq from NYSE

Xerox Holdings Corporation has made an important announcement regarding its listing on Stock Exchange. The firm has revealed that it has decided to...

Cal-Bay International Make a Strong Entry in NFT Market

Cal-Bay International, Inc. has disclosed that it has decided to make an entry into the fast-growing Non-Fungible Tokens (NFT) and digital asset market....

Kadmon [NASDAQ: KDMN] to be Acquired by Sanofi

Kadmon Holdings, Inc. disclosed that it has inked a definitive agreement with Sanofi . As per the agreement, Kadmon Holdings will be purchased...

Bitcoin Becomes Legal Tender in El Salvador

Bitcoin has finally managed to gain a reputation in El Salvador as it became a legal Tender in El Salvador now. This is the...

Binance Announces Plans to Limit Services for Singapore Market

The Binance cryptocurrency exchange has disclosed that it has decided to limit the services for the Singapore market. Binance revealed that by September 10,...